ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GSK Gsk Plc

1,436.00
16.60 (1.17%)
01 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  16.60 1.17% 1,436.00 1,436.00 1,436.60 1,442.20 1,419.00 1,426.00 5,243,528 16:35:05
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 34.91B 14.96B 3.6522 3.93 58.82B

Gsk Share Discussion Threads

Showing 31101 to 31121 of 32800 messages
Chat Pages: Latest  1252  1251  1250  1249  1248  1247  1246  1245  1244  1243  1242  1241  Older
DateSubjectAuthorDiscuss
16/9/2022
11:41
AZN continues to power ahead......
spoole5
16/9/2022
07:23
https://www.google.com/amp/s/capital.com/amp/cury-currys-share-price-double
blackhorse23
16/9/2022
06:54
$1.14 = £1, is amazing for GSK earnings. Quarterly results on 2nd November will make good reading .... :0)
tradermichael
14/9/2022
11:34
Good day uppompeii

Long time no speak.

"So is this worth a buy?"
========================

At some point yes.

Knowing how you like a chart I thought you would appreciate this one

SP currently resting on the 78.6% fib.

Difficult to avoid the thought that 1200 beckons. The pink dashed line indicates the low in 2015 and 2018 so it may come to the 'rescue'.

Best keep an eye on the fib support.

GSK DAILY

bracke
13/9/2022
12:11
Jonjo, a good point, thanks. I've tidied up my post now to give the thread more logical continuity!
tradermichael
13/9/2022
11:44
So is this worth a buy?
uppompeii
13/9/2022
11:32
TM
you are a victim of 'post hoc ergo propter hoc'. This site loses it integrity by allowing posters to edit after their post has been replied to. Thereby rendering your post meaningless. Shouldn't be allowed.

jonjoneil
12/9/2022
08:08
As the largest consumer healthcare business in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers and Centrum vitamins, Haleon is a global leader in over the counter medicines with a 7.3 percent market share. Market capitalisation of £20bn is unrealistically cheap and is probably worth double that valuation!
tradermichael
12/9/2022
07:55
Yet everyone now knows Haleon is worth less than half that and probably alot less than £20 billion!
paul planet earth
12/9/2022
07:43
Nope: the saving grace is that a WELL-RESPECTED MAN in the industry - the head of Unilevel thinks HLN is worth MORE THAN £50b.....

That my friend is something you cannot keep hiding from.

netcurtains
12/9/2022
07:40
Re the Unilever £50bn bid.
I think the only saving grace for our Emma is that Unilever shareholder's were not expected to vote through the acquisition at the suggested price.

ie the bid wasn't firm and set in stone, still needing to be sold to UNL stockholders.

But what a disaster so far Haleon, and GSK.

geckotheglorious
12/9/2022
06:47
...so you think a MAN who offers £50b is great but you think HLN is worth less than half the £50b....

Your position is so shot full of logical flaws I dont know where to begin.

I can no longer take the shorters seriously, they do not know what they are doing.

netcurtains
12/9/2022
02:59
MRF - couldn't have put it better.
unastubbs
11/9/2022
22:16
The Haleon IPO was a total and utter financial diaster especially as Unilver offered £50 billion in December..
paul planet earth
11/9/2022
22:15
The first claim on earnings is debt holders servicing of interest and repayment of debt not shareholders..Hence to ignore the value of debt on an enterprise value is pure ignorance. Haleon IPO failed because the balance sheet was over loaded with debt, 4 years to repay, which killed off any pension fund interest..With interest rates rising fast that debt burden will rise on debt maturity assuming Haleon is still trading then and not bought out by a rival and asset stripped.
paul planet earth
10/9/2022
15:31
Zho: it’s possible I guess which thus proves HLN is MASSIVELY undervalued or more likely the FT is just wrong
netcurtains
10/9/2022
14:32
>>The £50b clearly did not include the debt>>

I think it did. This is from the FT:

"But analysts said GSK would face questions about its refusal of a Unilever offer of £50bn — a figure that also accounted for £10bn of debt — for the division late last year."

zho
10/9/2022
13:59
"The £50b clearly did not include the debt.
So you can argue tht GSK is worth £25b more than it is now
as it does not have the debt that went to HLN."

The debt was £10.3b

"I’ve often noticed that arrogance leads to inconsistent problems in analysis of data"

for "arrogance" read ignorance

jonjoneil
10/9/2022
13:48
I disagree that net debt of X equates to 1-X share price.
I think FEAR of debt drives price down more than the value of the debt.
The poster appeared not to realise this.
I’ve often noticed that arrogance leads to inconsistent problems in analysis of data

netcurtains
10/9/2022
13:33
Net - how can you disagree with a fact. The person who marked your post up is retarded
There is no integrity left here

jonjoneil
10/9/2022
12:00
For information - the amount of debt transferred to Haleon from GSK was £10.3b
post 30882 above is just misleading rubbish

jonjoneil
Chat Pages: Latest  1252  1251  1250  1249  1248  1247  1246  1245  1244  1243  1242  1241  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com